U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Grade 2 Duodenum Ulcer, CTCAE

MedGen UID:
286599
•Concept ID:
C1559478
•
Finding

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVGrade 2 Duodenum Ulcer, CTCAE

Professional guidelines

PubMed

Repeated Treatment with (90)Y-Microspheres in Intrahepatic Cholangiocarcinoma Relapsed After the First Radioembolization.
Filippi L, Di Costanzo GG, Tortora R, Pelle G, Cianni R, Schillaci O, Bagni O
Cancer Biother Radiopharm 2019 May;34(4):231-237. Epub 2019 Feb 13 doi: 10.1089/cbr.2018.2718. PMID: 30758985

Recent clinical studies

Etiology

Repeated Treatment with (90)Y-Microspheres in Intrahepatic Cholangiocarcinoma Relapsed After the First Radioembolization.
Filippi L, Di Costanzo GG, Tortora R, Pelle G, Cianni R, Schillaci O, Bagni O
Cancer Biother Radiopharm 2019 May;34(4):231-237. Epub 2019 Feb 13 doi: 10.1089/cbr.2018.2718. PMID: 30758985

Therapy

Repeated Treatment with (90)Y-Microspheres in Intrahepatic Cholangiocarcinoma Relapsed After the First Radioembolization.
Filippi L, Di Costanzo GG, Tortora R, Pelle G, Cianni R, Schillaci O, Bagni O
Cancer Biother Radiopharm 2019 May;34(4):231-237. Epub 2019 Feb 13 doi: 10.1089/cbr.2018.2718. PMID: 30758985

Prognosis

Repeated Treatment with (90)Y-Microspheres in Intrahepatic Cholangiocarcinoma Relapsed After the First Radioembolization.
Filippi L, Di Costanzo GG, Tortora R, Pelle G, Cianni R, Schillaci O, Bagni O
Cancer Biother Radiopharm 2019 May;34(4):231-237. Epub 2019 Feb 13 doi: 10.1089/cbr.2018.2718. PMID: 30758985

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...